Electrochemical oxidation of mitoxantrone at a glassy carbon electrode

Mitoxantrone is an anthracycline used as an antitumour antibiotic for leukaemia and breast cancer treatment, due to its interaction with DNA. However, the molecular mechanism of the antitumour action is not completely understood. Using a glassy carbon electrode the electrochemical oxidation of mitoxantrone was shown to be a complex, pH-dependent, irreversible electrode process involving several metabolites. Comparison of the electrochemical oxidation behaviour of mitoxantrone, ametantrone and aminantrone enabled a deeper understanding of the mechanism and showed the relevance of electrochemical data for the understanding of the cytotoxicity of mitoxantrone. Since mitoxantrone and its oxidation products adsorb strongly on the electrode surface, causing severe problems of electrode fouling, reproducible electroanalytical determinations could only be done at very low concentrations and in an aqueous buffer supporting electrolyte containing 30% ethanol. The detection limit obtained was 10 ˇ7 M. # 1999 Elsevier Science B.V. All rights reserved.

[1]  M. Waring,et al.  DNA recognition by two mitoxantrone analogues: Influence of the hydroxyl groups , 1996, FEBS letters.

[2]  R. Angier,et al.  Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. , 1979, Journal of medicinal chemistry.

[3]  K. J. Miller,et al.  Interactions of molecules with nucleic acids. VI. Computer design of chromophoric intercalating agents , 1982, Biopolymers.

[4]  P. Gutiérrez,et al.  Mechanism(s) for the metabolism of mitoxantrone: electron spin resonance and electrochemical studies. , 1990, Chemico-biological interactions.

[5]  M. Perry.  The Chemotherapy Source Book , 1992, Annals of Internal Medicine.

[6]  I. Tannock,et al.  Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. , 1997, British Journal of Cancer.

[7]  R. K. Zee-Cheng,et al.  Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones. , 1978, Journal of medicinal chemistry.

[8]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[9]  D. Waidelich,et al.  Evidence for oxidative activation of mitoxantrone in human, pig, and rat. , 1991, Drug Metabolism And Disposition.

[10]  A. Kettle,et al.  Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. , 1995, Anti-cancer drug design.

[11]  I. Smith,et al.  Mitoxantrone (novantrone): a review of experimental and early clinical studies. , 1983, Cancer treatment reviews.

[12]  J. Lown,,et al.  Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone. , 1988, Free radical biology & medicine.

[13]  W. Wilson,et al.  Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. , 1985, Biochemistry.

[14]  M. Saraste,et al.  FEBS Lett , 2000 .

[15]  J. Lown,,et al.  Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug. , 1989, Biochemical pharmacology.

[16]  A. Kettle,et al.  Oxidative metabolism of mitoxantrone by the human neutrophil enzyme myeloperoxidase. , 1994, Biochemical pharmacology.

[17]  R. Gebhardt,et al.  Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. , 1993, Cancer research.

[18]  G. R. Fisher,et al.  DNA strand breakage by peroxidase‐activated mitoxantrone , 1991, The Journal of pharmacy and pharmacology.